Novonesis A/s Class B · OMXCOP:NSIS_B

Novonesis A/s Class B — Novozymes — 9M 2014 Earnings Presentation

8 slides from Novonesis A/s Class B's earnings presentation, Oct 23, 2014

  1. Slide 1: Conference Call 9M 2014

    CONFERENCE CALL 9M 2014 October 23, 2014

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation and its related comments contain forward- looking statements, including financial expectations. Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to differ materially from expectations. Th

  3. Slide 3: 9M 2014 Summary

    9M 2014 Summary Sales growth on track Sales and organic growth • 8% organic sales growth 9M 2012 – 9M 2014 DKKm • 3 %-points negative impact from currencies 10% 9,600 8% 7% • Sales growth as expected in Q3 with 9% organic 8% 6% 9,200 9,278 sales growth 6% 8,800 4% 8,806 Continued strong financial pe

  4. Slide 4: Sales & Markets

    Sales & Markets  9M 2014 sales: DKK +5%, LCY +8%, organic +8% Sales by industry, DKKm 9M 2014 9M 2013  Q3 2014 sales: DKK +8%, LCY +9%, organic +9% • Household Care: Sales as expected; Q3 growth up Household 3,262 from Q2 due to innovation and growth in emerging +3%/+5% Care 3,156 markets. Develop

  5. Slide 5: Business Development Update

    Business Development Update Positive developments within Biomass conversion • Novozymes recognized as world • POET-DSM, Abengoa and Granbio started production in Q3. leader for corporate action on climate change by The Carbon • DuPont and Raizen expected to start up in Q4, 2014. Disclosure Project (

  6. Slide 6: R&D Activity update

    R&D Activity update New innovation in Q3 Ramp-up in BioAg R&D • Household Care: Medley®; a blended formulation that enables • Good progress in the collaboration easier application of more enzymes. Medley is targeted toward with Monsanto. small and medium producers. • 170.000 field tests progressing

  7. Slide 7: 9M 2014 Financial Performance

    9M 2014 Financial Performance Strong financial performance in 9M’14 2014 2014 Realized Outlook Outlook • +1 %-point underlying improvement in gross margin Key financials 9M 2014 Oct. 23 Aug. 14 despite currency headwind due to continued productivity improvements, lower raw material costs Sales growt

  8. Slide 8: Novozymes - Rethink Tomorrow

    novozymes’ Rethink Tomorrow

Novozymes — 9M 2014 Earnings Presentation on 6ix